Researchers tested VER-01, a cannabis-derived extract, on adults suffering persistent lower back pain. Patients reported meaningful pain relief over several months. Scientists developed VER-01 to reduce pain without causing addiction or severe side effects. Chronic lower back pain affects around 619 million people globally, making it the leading cause of disability. Traditional treatments like opioids carry high addiction risks, while NSAIDs, including ibuprofen, can harm the heart and digestive system. Many patients struggle to find effective alternatives, highlighting a critical need for safer therapies.
Clinical Trial Shows Measurable Benefits
The study enrolled 820 adults who failed to respond to non-opioid medications. Researchers divided participants into two groups: one received VER-01, while the other took a placebo. Patients recorded pain on a 0–10 scale, with 10 representing maximum pain. After three months, VER-01 users reported a 1.9-point reduction, compared to 0.6 for the placebo group. A six-month extension showed an additional 1.1-point decline in pain, along with better sleep quality and improved mobility. Scientists published the findings in Nature Medicine. Jan Vollert, an independent neuroscience expert, called the results clinically significant and encouraging, while cautioning that further studies are necessary to confirm long-term effects.
Safety Profile and Key Differences from Smoking
VER-01 contains 2.5 milligrams of THC per dose, alongside other cannabis-derived compounds. Patients mainly experienced mild dizziness, nausea, and temporary sleepiness. Researchers observed no signs of dependence or abuse. Experts stress that VER-01 differs completely from smoking cannabis. Jan Vollert compared it to eating hazelnuts versus consuming Nutella: they share origins but differ significantly in effects. Scientists plan to compare VER-01 directly with opioids in future trials. If successful, VER-01 could provide a safe, effective option for millions struggling with chronic lower back pain worldwide.
